Evommune
PublicEvommune is now publicly traded
The data on this page reflects Evommune's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series C
Oct 31, 2024
Total Funding Raised
$318M
Company Overview
Evommune operates in Biotech and is based in Palo Alto, California. It has raised $318M.
Evommune is a biotechnology company that develops innovative treatments targeting the root causes of inflammatory diseases to enhance patient quality of life.
Sector
Biotech
Verticals
Life Sciences
AI Layer
Non-AI
Evommune Comparables
Compare Evommune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attovia Therapeutics | 82% | |
| Jasper Therapeutics | 80% | |
| Septerna | 80% |
For institutional investors. Book with your work email.
Evommune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 31, 2024 | ||||
| Series B | Jun 28, 2023 | ||||
| Series B | Mar 28, 2023 | ||||
| Series A | Sep 9, 2021 | ||||
| Seed | Nov 18, 2020 |
For institutional investors. Book with your work email.
Evommune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Series C |
| SymBiosis Capital Management | Series C, Series B |
| ADAR1 Capital Management | Series C |
| RA Capital Management | Series C |
| EQT Life Sciences | Series C, Series A, Series B |
| Amplitude Ventures | Series B, Series C |
| Andera Partners | Series B, Series C, Series A |
For institutional investors. Book with your work email.
Evommune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.